Skip to main content
Vassiliki Boussiotis, MD, Oncology, Boston, MA

VassilikiABoussiotisMD

Oncology • Boston, MA

Hematologic Oncology

Professor, Medicine-Beth Israel Deaconess Medical Center, Harvard Medical School

Join to view full profile

Dr. Boussiotis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Boussiotis' full profile

Already have an account?

  • Office

    100 Blossom St
    Hematology Oncology Associates Cox 2
    Boston, MA 02114
    Phone+1 617-724-3200
    Fax+1 617-726-2894

Education & Training

  • UMass Chan Medical School
    UMass Chan Medical SchoolResidency, Internal Medicine, 2004 - 2004
  • University of Athens
    University of AthensClass of 1982

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2004 - 2026

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
    Vassiliki A Boussiotis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Metabolic Reprogramming of Myeloid Cells in Response to Factors of “Emergency” Myelopoiesis By Myeloid-Specific PD-1 Ablation, Regulates Myeloid Lineage Fate Commitmen... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology
    NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-OncologyApril 15th, 2021
  • NanoView, Beth Israel Deaconess Medical Center Launch Immuno-Oncology Biomarker Study
    NanoView, Beth Israel Deaconess Medical Center Launch Immuno-Oncology Biomarker StudyApril 15th, 2021
  • CD39+PD-1+CD8+ T Cells Mediate Metastatic Dormancy in Breast Cancer
    CD39+PD-1+CD8+ T Cells Mediate Metastatic Dormancy in Breast CancerFebruary 3rd, 2021
  • Join now to see all

Grant Support

  • Prevention Of Acute GVHD By Inhibition Of CDK2National Heart, Lung, And Blood Institute2011–2012
  • The Role Of RAP1 And Its Novel Associated Molecules In T Cell ResponsesNational Institute Of Allergy And Infectious Diseases2011
  • The Role Of RAP1 In T-Cell ResponsesNational Institute Of Allergy And Infectious Diseases2008–2009
  • Reconstitution Of T Cell Immunity After UCB Transplantation: The Role Of TregNational Cancer Institute2008–2009
  • Expression And Function Of TOB In T LymphocytesNational Cancer Institute2008–2009
  • The Role Of RAP1 In T-Cell ResponsesNational Institute Of Allergy And Infectious Diseases2005–2008
  • Expression And Function Of TOB In T LymphocytesNational Cancer Institute2005–2007
  • The Role Of RAP1 In T-Cell ResponsesNational Institute Of Allergy And Infectious Diseases2003
  • The Role Of P27KIP1 In T-Cell ResponsesNational Institute Of Allergy And Infectious Diseases2001–2003
  • RAP1 And Associated Molecules And T Cell AnergyNational Institute Of Allergy And Infectious Diseases1998–2002

Dr. Vassiliki Boussiotis, Dr. Vassiliki Boussiotis, MD, Dr. V Boussiotis, Dr. Vassiliki A Boussiotis